1
|
Updates on the Epidemiology of the Human T-Cell Leukemia Virus Type 1 Infection in the Countries of the Eastern Mediterranean Regional Office of the World Health Organization with Special Emphasis on the Situation in Iran. Viruses 2022; 14:v14040664. [PMID: 35458394 PMCID: PMC9029775 DOI: 10.3390/v14040664] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 03/12/2022] [Accepted: 03/21/2022] [Indexed: 02/04/2023] Open
Abstract
Background: The epidemiology and prevalence of the Human T-cell leukemia virus type-1 (HTLV-1) infection represent a recommended priority by global health agencies. An in-depth revision to update the status of this infection in countries including those of the Eastern Mediterranean Regional Office (EMRO) of the World Health Organization is hence required. Methods: Ninety-seven studies evaluating the HTLV-1 infection in low- and high-risk populations in EMRO countries were retrieved from the international electronic databases and were used to assess the epidemiological status of the infection in these countries. Results: Most epidemiologic reports were published from Iran, with more than 50% of Iranian prisoners and around 4% of healthy individuals reported to have the infection. In Egypt, a considerable prevalence of the virus spans around 1.11% of blood donors. Foci of HTLV-1 infection are also present in some countries and require a careful epidemiological evaluation. In the other EMRO countries, a lower prevalence that does not exceed 1% was reported. Conclusion: The epidemiology and prevalence of HTLV-1 in the EMRO countries require a tight revision and update. Published studies reveal a scarce distribution of the virus in the African countries of EMRO, while a lower prevalence is denoted in the Asian countries of EMRO, except in Iran, where the prevalence is high.
Collapse
|
2
|
Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities. Curr Oncol Rep 2021; 23:141. [PMID: 34735653 DOI: 10.1007/s11912-021-01138-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/14/2021] [Indexed: 10/19/2022]
Abstract
PURPOSE OF THE REVIEW Adult T-cell leukemia (ATL) is an aggressive chemo-resistant malignancy secondary to HTLV-1 retrovirus. Prognosis of ATL remains dismal. Herein, we emphasized on the current ATL treatment modalities and their drawbacks, and opened up on promising targeted therapies with special focus on the HTLV-1 regulatory proteins Tax and HBZ. RECENT FINDINGS Indolent ATL and a fraction of acute ATL exhibit long-term survival following antiviral treatment with zidovudine and interferon-alpha. Monoclonal antibodies such as mogamulizumab improved response rates, but with little effect on survival. Allogeneic hematopoietic cell transplantation results in long-term survival in one third of transplanted patients, alas only few patients are transplanted. Salvage therapy with lenalidomide in relapsed/refractory patients leads to prolonged survival in some of them. ATL remains an unmet medical need. Targeted therapies focusing on the HTLV-1 viral replication and/or viral regulatory proteins, as well as on the host antiviral immunity, represent a promising approach for the treatment of ATL.
Collapse
|
3
|
Echevarria-Lima J, de Abreu Pereira D, de Oliveira TS, de Melo Espíndola O, Lima MA, Celestino Leite AC, Sandim V, Rodrigues Nascimento C, E Kalume D, B Zingali R. Protein Profile of Blood Monocytes is Altered in HTLV-1 Infected Patients: Implications for HAM/TSP Disease. Sci Rep 2018; 8:14354. [PMID: 30254298 PMCID: PMC6156329 DOI: 10.1038/s41598-018-32324-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Accepted: 08/12/2018] [Indexed: 12/27/2022] Open
Abstract
Human T-cell lymphotropic virus type-1 (HTLV-1) is the etiological agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The endothelial breakdown and migration of leukocytes, including monocytes, to the spinal cord are involved in HAM/TSP development. Monocytes from HTLV-1-infected individuals exhibit important functional differences when compared to cells from uninfected donors. Using proteomic shot gun strategy, performed by nanoACQUITY-UPLC system, we analyzed monocytes isolated from peripheral blood of asymptomatic carriers (AC), HAM/TSP and uninfected individuals. 534 proteins were identified among which 376 were quantified by ExpressionE software. Our study revealed a panel of changes in protein expression linked to HTLV-1 infection. Upregulation of heat shock proteins and downregulation of canonical histone expression were observed in monocytes from HTLV-1-infected patients. Moreover, expression of cytoskeleton proteins was increased in monocytes from HTLV-1-infected patients, mainly in those from HAM/TSP, which was confirmed by flow cytometry and fluorescence microscopy. Importantly, functional assays demonstrated that monocytes from HAM/TSP patients present higher ability for adhesion and transmigration thought endothelium than those from AC and uninfected individuals. The major changes on monocyte protein profile were detected in HAM/TSP patients, suggesting that these alterations exert a relevant role in the establishment of HAM/TSP.
Collapse
Affiliation(s)
- Juliana Echevarria-Lima
- Lab. de Imunologia Básica e Aplicada, Depto. of Immunology, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
| | - Denise de Abreu Pereira
- Unidade de Espectrometria de Massas e Proteômica (UEMP), Instituto de Bioquímica Médica Leopoldo de Meis and Instituto Nacional de Biologia Estrutural e Bioimagem (INBEB), UFRJ, Rio de Janeiro, RJ, Brazil
- Programa de Oncobiologia Celular e Molecular, Coordenação Geral de Ensino e Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil
| | - Thais Silva de Oliveira
- Lab. de Imunologia Básica e Aplicada, Depto. of Immunology, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
| | - Otávio de Melo Espíndola
- Lab. de Pesquisa Clínica em Neuroinfecções, Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
| | - Marco Antonio Lima
- Lab. de Pesquisa Clínica em Neuroinfecções, Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
| | - Ana Cláudia Celestino Leite
- Lab. de Pesquisa Clínica em Neuroinfecções, Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
| | - Vanessa Sandim
- Unidade de Espectrometria de Massas e Proteômica (UEMP), Instituto de Bioquímica Médica Leopoldo de Meis and Instituto Nacional de Biologia Estrutural e Bioimagem (INBEB), UFRJ, Rio de Janeiro, RJ, Brazil
| | | | - Dario E Kalume
- Lab. Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil
| | - Russolina B Zingali
- Unidade de Espectrometria de Massas e Proteômica (UEMP), Instituto de Bioquímica Médica Leopoldo de Meis and Instituto Nacional de Biologia Estrutural e Bioimagem (INBEB), UFRJ, Rio de Janeiro, RJ, Brazil
| |
Collapse
|
4
|
Taylor GP. Human T-lymphotropic virus type 1 infection and solid organ transplantation. Rev Med Virol 2018; 28. [PMID: 29380451 DOI: 10.1002/rmv.1970] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2017] [Revised: 12/14/2017] [Accepted: 12/18/2017] [Indexed: 11/06/2022]
Abstract
HTLV infection appears to be more common among renal transplant candidates than in the related general population. HTLV-1-associated diseases may occur in carriers who are transplanted but there is insufficient evidence to confirm whether these occur more frequently as a result of the associated immunosuppression. Consequently, pre-existing HTLV-1 infection should not be considered a contra-indication to transplantation. The risk of transmission of HTLV-1 through solid organ transplantation from a confirmed infected donor is unknown. There are anecdotes of multiple infections from a single donor. Biologically due to the significant volume of blood and the lack of storage, transmission would be expected to be higher than following blood transfusion. The rate of subsequent disease is unknown, but there are now 11 reports of HAM and 2 of ATL occurring within 4 years of transplantation associated infection. There are insufficient data to know whether the time from infection to onset of disease and the rate of progression differ from transmission through other routes, but early onset and rapid progression is a concern. Responses to enhanced immunosuppression for the treatment of HAM are variable. The risk of HTLV-1 associated disease in exchange for a life-saving major organ transplantation from an infected donor might be considered worth taking by some HTLV-1 uninfected patients. Peri-transplantation antiretroviral prophylaxis with zidovudine and raltegravir is biologically sound but therapeutically unproven. The risks related to HTLV-1 infection appear to preclude the use of any other tissue. All transplant donors should be screened for HTLV-1 infection regardless of perceived risk.
Collapse
Affiliation(s)
- Graham P Taylor
- Professor of Human Retrovirology, Department of Medicine, Imperial College London, London, UK
| |
Collapse
|
5
|
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a mature T-cell neoplasm with extremely poor prognosis caused by human T-cell leukemia virus type 1 (HTLV-1). The distribution of HTLV-1 and the incidence of ATLL in endemic areas have been well described, however, little is known about the incidences and the trends of the disease in nonendemic areas. Recently, studies have shown that the HTLV-1 carriers are increasing in nonendemic areas. Also, the incidence of ATLL seems to be significantly increasing in nonendemic areas suggesting that HTLV-1 carriers have emigrated from endemic areas. These epidemiologic studies indicate the necessity of edification of the disease caused by HTLV-1 and establishing appropriate preventive methods against infection in nonendemic areas.
Collapse
Affiliation(s)
- Noriaki Yoshida
- Department of Pathology, Kurume University School of Medicine, Kurume, Japan
| | | |
Collapse
|
6
|
Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Piccinini V, Liumbruno GM, Grazzini G. Human T-lymphotropic virus and transfusion safety: does one size fit all? Transfusion 2015; 56:249-60. [PMID: 26388300 DOI: 10.1111/trf.13329] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Revised: 07/28/2015] [Accepted: 08/02/2015] [Indexed: 12/17/2022]
Abstract
Human T-cell leukemia viruses (HTLV-1 and HTLV-2) are associated with a variety of human diseases, including some severe ones. Transfusion transmission of HTLV through cellular blood components is undeniable. HTLV screening of blood donations became mandatory in different countries to improve the safety of blood supplies. In Japan and Europe, most HTLV-infected donors are HTLV-1 positive, whereas in the United States a higher prevalence of HTLV-2 is reported. Many industrialized countries have also introduced universal leukoreduction of blood components, and pathogen inactivation technologies might be another effective preventive strategy, especially if and when generalized to all blood cellular products. Considering all measures available to minimize HTLV blood transmission, the question is what would be the most suitable and cost-effective strategy to ensure a high level of blood safety regarding these viruses, considering that there is no solution that can be deemed optimal for all countries.
Collapse
Affiliation(s)
| | - Stefania Vaglio
- Italian National Blood Centre, National Institute of Health.,Department of Clinical and Molecular Medicine, "Sapienza" University of Rome, Rome, Italy
| | | | - Giuseppina Facco
- Italian National Blood Centre, National Institute of Health.,Immunohaemathology and Transfusion Medicine Unit, Azienda Ospedaliera Città Della Salute e Della Scienza, Turin, Italy
| | | | | | | | | |
Collapse
|
7
|
Modulation of glutathione intracellular levels alters the spontaneous proliferation of lymphocyte from HTLV-1 infected patients. Immunobiology 2013; 218:1166-74. [DOI: 10.1016/j.imbio.2013.04.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2012] [Accepted: 04/05/2013] [Indexed: 11/17/2022]
|
8
|
Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol 2012; 3:388. [PMID: 23162541 PMCID: PMC3498738 DOI: 10.3389/fmicb.2012.00388] [Citation(s) in RCA: 941] [Impact Index Per Article: 78.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2012] [Accepted: 10/18/2012] [Indexed: 01/12/2023] Open
Abstract
The human T-cell leukemia virus type 1 (HTLV-1), identified as the first human oncogenic retrovirus 30 years ago, is not an ubiquitous virus. HTLV-1 is present throughout the world, with clusters of high endemicity located often nearby areas where the virus is nearly absent. The main HTLV-1 highly endemic regions are the Southwestern part of Japan, sub-Saharan Africa and South America, the Caribbean area, and foci in Middle East and Australo-Melanesia. The origin of this puzzling geographical or rather ethnic repartition is probably linked to a founder effect in some groups with the persistence of a high viral transmission rate. Despite different socio-economic and cultural environments, the HTLV-1 prevalence increases gradually with age, especially among women in all highly endemic areas. The three modes of HTLV-1 transmission are mother to child, sexual transmission, and transmission with contaminated blood products. Twenty years ago, de Thé and Bomford estimated the total number of HTLV-1 carriers to be 10-20 millions people. At that time, large regions had not been investigated, few population-based studies were available and the assays used for HTLV-1 serology were not enough specific. Despite the fact that there is still a lot of data lacking in large areas of the world and that most of the HTLV-1 studies concern only blood donors, pregnant women, or different selected patients or high-risk groups, we shall try based on the most recent data, to revisit the world distribution and the estimates of the number of HTLV-1 infected persons. Our best estimates range from 5-10 millions HTLV-1 infected individuals. However, these results were based on only approximately 1.5 billion of individuals originating from known HTLV-1 endemic areas with reliable available epidemiological data. Correct estimates in other highly populated regions, such as China, India, the Maghreb, and East Africa, is currently not possible, thus, the current number of HTLV-1 carriers is very probably much higher.
Collapse
Affiliation(s)
- Antoine Gessain
- Département de Virologie, Unité d'épidémiologie et physiopathologie des virus oncogènes, Institut Pasteur Paris, France ; CNRS, URA3015 Paris, France
| | | |
Collapse
|
9
|
Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol 2012; 3:322. [PMID: 22973265 PMCID: PMC3437524 DOI: 10.3389/fmicb.2012.00322] [Citation(s) in RCA: 169] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2012] [Accepted: 08/20/2012] [Indexed: 11/13/2022] Open
Abstract
Adult T-cell leukemia (ATL) is an aggressive T-cell malignancy caused by human T-cell leukemia virus type I (HTLV-1) infection and often occurs in HTLV-1-endemic areas, such as southwestern Japan, the Caribbean islands, Central and South America, Intertropical Africa, and Middle East. To date, many epidemiological studies have been conducted to investigate the incidence of ATL among general population or HTLV-1 carriers and to identify a variety of laboratory, molecular, and host-specific markers to be possible predictive factors for developing ATL because HTLV-1 infection alone is not sufficient to develop ATL. This literature review focuses on the epidemiology of ATL and the risk factors for the development of ATL from HTLV-1 carriers, while keeping information on the epidemiology of HTLV-1 to a minimum. The main lines of epidemiological evidence are: (1) ATL occurs mostly in adults, at least 20-30 years after the HTLV-1 infection, (2) age at onset differs across geographic areas: the average age in the Central and South America (around 40 years old) is younger than that in Japan (around 60 years old), (3) ATL occurs in those infected in childhood, but seldom occurs in those infected in adulthood, (4) male carriers have about a three- to fivefold higher risk of developing ATL than female, (5) the estimated lifetime risk of developing ATL in HTLV-1 carriers is 6-7% for men and 2-3% for women in Japan, (6) a low anti-Tax reactivity, a high soluble interleukin-2 receptor level, a high anti-HTLV-1 titer, and high levels of circulating abnormal lymphocytes and white blood cell count are accepted risk factors for the development of ATL, and (7) a higher proviral load (more than 4 copies/100 peripheral blood mononuclear cells) is an independent risk factor for progression of ATL. Nevertheless, the current epidemiological evidence is insufficient to fully understand the oncogenesis of ATL. Further well-designed epidemiological studies are needed.
Collapse
Affiliation(s)
- Masako Iwanaga
- Graduate School of Public Health, Teikyo University Tokyo, Japan
| | | | | |
Collapse
|
10
|
Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). Leuk Res 2012; 36:857-61. [DOI: 10.1016/j.leukres.2011.12.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2011] [Revised: 12/02/2011] [Accepted: 12/06/2011] [Indexed: 11/20/2022]
|
11
|
Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, Kumaran T, Ardeshna KM, Pagliuca A, Taylor GP, Fields PA. Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma. J Clin Oncol 2011; 29:4696-701. [DOI: 10.1200/jco.2011.35.5578] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose Adult T-cell leukemia/lymphoma (ATLL) is a mature (post-thymic) T-cell lymphoma associated with human T-lymphotropic virus type 1 infection. Survival in aggressive subtypes remains poor, and treatment resistance is frequent. Use of zidovudine (ZDV) and interferon alfa (IFN-α) has been associated with improved response rates in small studies and prolonged overall survival in leukemic ATLL subtypes in a recent meta-analysis. Patients and Methods We report the clinicopathologic characteristics, treatment, and outcome of 73 patients with aggressive ATLL (acute ATLL, 29; lymphoma ATLL, 44) diagnosed and treated in England between 1999 and 2009. The impact of ZDV/IFN-α on treatment response and survival was assessed. Results The overall response rate ranged from 49% with chemotherapy alone to 81% with combined first-line therapy (chemotherapy with concurrent/sequential ZDV/IFN-α). Median overall survival (OS) was 9 months: 7.5 months for acute ATLL and 10 months for lymphoma ATLL. Use of ZDV/IFN-α at any time prolonged survival in acute (P < .001) and lymphoma ATLL (P < .001) and was the sole factor associated with reduction in risk of death in aggressive ATLL (hazard ratio, 0.23; 95% CI, 0.09 to 0.60; P = .002). Combined first-line therapy prolonged median OS in acute (P = .0081) and lymphoma ATLL (P = .001) compared with chemotherapy alone. Conclusion These data support the use of low-dose ZDV/IFN-α with chemotherapy in first-line treatment of acute and lymphoma ATLL.
Collapse
Affiliation(s)
- Andrew Hodson
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Siobhan Crichton
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Silvia Montoto
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Naheed Mir
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Estella Matutes
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Kate Cwynarski
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Thurai Kumaran
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Kirit M. Ardeshna
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Antonio Pagliuca
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Graham P. Taylor
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| | - Paul A. Fields
- Andrew Hodson, National Centre for Human Retrovirology, St Mary's Hospital, Imperial College Healthcare National Health Service (NHS) Trust; Siobhan Crichton, King's College London; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London; Naheed Mir, University Hospital Lewisham NHS Trust; Estella Matutes, Royal Marsden NHS Foundation Trust; Kate Cwynarski, Royal Free Hampstead NHS Trust; Thurai Kumaran, North Middlesex University Hospital; Kirit M. Ardeshna, University College Hospital
| |
Collapse
|
12
|
The hematopathologist as detective. J Hematop 2011. [DOI: 10.1007/s12308-011-0098-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
13
|
Abstract
AbstractHuman T-cell lymphotropic virus type 1 (HTLV-1) is a causative agent of adult T-cell leukemia and HTLV-1–associated myelopathy/tropical spastic paraparesis. HTLV-1–associated myelopathy/tropical spastic paraparesis is a chronic inflammatory disease characterized by loss of motor movement in response to spinal marrow cell destruction by T lymphocytes. To perform their cellular function, T cells need to be activated by antigen-presenting cells, such as dendritic cells (DCs). The aim of this work was to analyze DC differentiation and activation from monocytes of HTLV-1–infected individuals. We demonstrated that monocytes from HTLV-1–infected patients who had been stimulated to differentiate had an impaired loss of CD14 expression, expressed low levels of CD1a, and maintained secretion of tumor necrosis factor-α compared with monocytes from noninfected donors. We further evaluated DC activation by tumor necrosis factor-α. We observed that in response to activation, DCs that were derived from noninfected donors had an increase in the percentage of CD83+, CD86+, and human leukocyte antigen-DR+ cells, whereas in DCs derived from HTLV-1–infected patients, the percentage of CD83+, CD86+, and human leukocyte antigen-DR+ cells remained similar to that of nonactivated cells. Moreover, these cells had an impaired capacity to stimulate allogeneic T lymphocytes. We demonstrated that DC maturation was altered in HTLV-1–infected patients, which could contribute to the development of HTLV-1–associated diseases.
Collapse
|
14
|
Bunn PA, Pacheco T. Lessons learned from the systematic evaluation of cutaneous T-cell lymphomas at the national cancer institute and the roadmap for future studies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2010; 10 Suppl 2:S74-9. [PMID: 20826402 DOI: 10.3816/clml.2010.s.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Paul A Bunn
- Department of Medicine, University of Colorado Cancer Center, University of Colorado Denver, Aurora
| | | |
Collapse
|
15
|
Polakowski N, Gregory H, Mesnard JM, Lemasson I. Expression of a protein involved in bone resorption, Dkk1, is activated by HTLV-1 bZIP factor through its activation domain. Retrovirology 2010; 7:61. [PMID: 20653953 PMCID: PMC2918529 DOI: 10.1186/1742-4690-7-61] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2010] [Accepted: 07/23/2010] [Indexed: 12/28/2022] Open
Abstract
Background Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukemia, a malignancy characterized by uncontrolled proliferation of virally-infected CD4+ T-cells. Hypercalcemia and bone lesions due to osteoclast-mediated bone resorption are frequently associated with more aggressive forms of the disease. The HTLV-1 provirus contains a unique antisense gene that expresses HTLV-1 basic leucine zipper (bZIP) factor (HBZ). HBZ is localized to the nucleus where it regulates levels of transcription by binding to certain cellular transcriptional regulators. Among its protein targets, HBZ forms a stable complex with the homologous cellular coactivators, p300 and CBP, which is modulated through two N-terminal LXXLL motifs in the viral protein and the conserved KIX domain in the coactivators. Results To determine the effects of these interactions on transcription, we performed a preliminary microarray analysis, comparing levels of gene expression in cells with wild-type HBZ versus cells with HBZ mutated in its LXXLL motifs. DKK1, which encodes the secreted Wnt signaling inhibitor, Dickkopf-1 (Dkk1), was confirmed to be transcriptionally activated by HBZ, but not its mutant. Dkk1 plays a major role in the development of bone lesions caused by multiple myeloma. In parallel with the initial findings, activation of Dkk1 expression by HBZ was abrogated by siRNA-mediated knockdown of p300/CBP or by a truncated form of p300 containing the KIX domain. Among HTLV-1-infected T-cell lines tested, the detection of Dkk1 mRNA partially correlated with a threshold level of HBZ mRNA. In addition, an uninfected and an HTLV-1-infected T-cell line transfected with an HBZ expression vector exhibited de novo and increased DKK1 transcription, respectively. In contrast to HBZ, The HTLV-1 Tax protein repressed Dkk1 expression. Conclusions These data indicate that HBZ activates Dkk1 expression through its interaction with p300/CBP. However, this effect is limited in HTLV-1-infected T-cell lines, which in part, may be due to suppression of Dkk1 expression by Tax. Consequently, the ability of HBZ to regulate expression of Dkk1 and possibly other cellular genes may only be significant during late stages of ATL, when Tax expression is repressed.
Collapse
Affiliation(s)
- Nicholas Polakowski
- East Carolina University, Department of Microbiology and Immunology, Brody School of Medicine, Greenville, NC 27834, USA.
| | | | | | | |
Collapse
|
16
|
Phillips AA, Shapira I, Willim RD, Sanmugarajah J, Solomon WB, Horwitz SM, Savage DG, Bhagat G, Soff G, Zain JM, Alobeid B, Seshan VE, O'Connor OA. A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma. Cancer 2010; 116:3438-46. [DOI: 10.1002/cncr.25147] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Shimamoto Y, Yamaguchi M, Miyamoto Y, Yamaguchi J, Kuribayashi N, Sato H, Nishimura J, Nawata H, Kozuru M, Shimoyama M. The Differences between Lymphoma and Leukemia Type of Adult T-cell Leukemia. Leuk Lymphoma 2009; 1:101-12. [DOI: 10.3109/10428199009042466] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
18
|
Shimamot Y, Suga K, Igarashi H, Nishimura J, Nawata H, Yamaguchi M. Differences Between Long- and Short-Term Survivors with Lymphoma Type of Adult T-Cell Leukemia. Leuk Lymphoma 2009; 2:301-5. [DOI: 10.3109/10428199009106465] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
19
|
Matutes E, Catovsky D. Mature T-Cell Leukemias and Leukemia/Lymphoma Syndromes: Review of Our Experience in 175 Cases. Leuk Lymphoma 2009; 4:81-91. [DOI: 10.3109/10428199109068049] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
20
|
Bitar N, Hajj HE, Houmani Z, Sabbah A, Otrock ZK, Mahfouz R, Zaatari G, Bazarbachi A. Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. Transfusion 2009; 49:1859-64. [PMID: 19453978 DOI: 10.1111/j.1537-2995.2009.02223.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative disorder caused by human T-cell leukemia virus type I (HTLV-I). HTLV-I is endemic in southern Japan, the Caribbean, Central and South America, certain areas of Africa, and the southeastern United States. In the Middle East, North East Iran, particularly the region of Mashhad, has been recognized as an endemic region. CASE REPORTS In this report, the first two cases of ATL diagnosed in Lebanon are described. The first patient of Lebanese origin presented with acute ATL. The second patient of Romanian origin developed acute ATL in early relapse after autologous transplantation for ATL. Both patients had lymphocytosis, severe hypercalcemia, and CD25+ T-cell immunophenotype on peripheral blood. In both patients, HTLV-I serology was positive by enzyme-linked immunosorbent assay and confirmed by Western blot and HTLV-I oncoprotein Tax expression was documented in the leukemic cells. Upon screening, seven direct family members of the first patient were HTLV-I positive; four of them were regular blood donors. CONCLUSIONS Screening blood donors for HTLV-I seropositivity is not currently performed in Lebanon. A large screening study in Lebanon is needed to confirm whether South Lebanon is a new endemic region for HTLV-I infection and to recommend mandatory screening of blood donors for HTLV-I infection.
Collapse
Affiliation(s)
- Nizar Bitar
- Hematology Oncology, Transfusion Medicine, Sahel Hospital, Lebanese University, Beirut, Lebanon.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Stein A, Boughton BJ. COMMON ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT WITH HYPERCALCAEMIA AND LYTIC BONE LESIONS. Br J Haematol 2008. [DOI: 10.1111/j.1365-2141.1988.00503.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Shimamoto Y, Matsuzaki M, Yamaguchi M. Vacuolated Burkitt-like cells in adult T-cell leukaemia/lymphoma. CLINICAL AND LABORATORY HAEMATOLOGY 2008; 14:155-7. [PMID: 1633686 DOI: 10.1111/j.1365-2257.1992.tb01073.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Y Shimamoto
- Department of Internal Medicine, Saga Medical School, Japan
| | | | | |
Collapse
|
23
|
Ohsugi T, Koito A. Current topics in prevention of human T-cell leukemia virus type i infection: NF-kappa B inhibitors and APOBEC3. Int Rev Immunol 2008; 27:225-53. [PMID: 18574738 DOI: 10.1080/08830180801939272] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Human T-cell leukemia virus type I (HTLV-I) is the first human retrovirus and causes adult T-cell leukemia/lymphoma (ATL). Constitutive activation of nuclear factor-kappa B (NF-kappa B) in the leukemic cells is essential for their growth and survival. Thus, NF-kappa B inhibitors have been attracting attention as a potential strategy to treat ATL. Recently, the field of retrovirus research has been stimulated by the discovery of an innate host defense factor, APOBEC3, against the retroviruses. HTLV-I is relatively resistant to the antiviral effects of APOBEC3. To clarify the resistance of HTLV-I against APOBEC3 might contribute to the design of effective therapeutic approaches.
Collapse
Affiliation(s)
- Takeo Ohsugi
- Division of Microbiology and Genetics, Center for Animal Resources and Development, Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
| | | |
Collapse
|
24
|
Moxoto I, Boa-Sorte N, Nunes C, Mota A, Dumas A, Dourado I, Galvão-Castro B. [Sociodemographic, epidemiological and behavioral profile of women infected with HTLV-1 in Salvador, Bahia, an endemic area for HTLV]. Rev Soc Bras Med Trop 2007; 40:37-41. [PMID: 17486251 DOI: 10.1590/s0037-86822007000100007] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2006] [Accepted: 01/19/2007] [Indexed: 11/21/2022] Open
Abstract
The objective was to describe the sociodemographic, epidemiological and behavioral characteristics of women infected with HTLV-1 (64) and uninfected women (66) in Salvador, Bahia. The serological diagnosis was obtained via Elisa, Western Blot and Immunofluorescence. Epidemiological and sociodemographic data were collected using a standardized questionnaire. The chi-squared or Fisher test was used for categorical data and ANOVA or Kruskal-Wallis (3 groups) and the T-test or Mann-Whitney (2 groups) were used for continuous data. Associated variables were adjusted using logistic regression. More than half (57.8%) of the seropositive women were asymptomatic. The symptomatic women (with HAM/TSP) had fewer years of education. Comparison between seronegative and seropositive women showed that blood transfusion, anal sex practices, first sexual intercourse before the age of 18 years and three or more sexual partners over women's lifetime were risk factors for HTLV-1 infection. The prevention of both sexual transmission and vertical transmission (breastfeeding) should be reinforced. Prenatal screening is of paramount importance.
Collapse
Affiliation(s)
- Ivanoska Moxoto
- Escola Bahiana de Medicina e Saúde Pública, Fundação Bahiana para o Desenvolvimento das Ciências, Salvador, BA, Brasil
| | | | | | | | | | | | | |
Collapse
|
25
|
Osborne GEN, Pagliuca A, Ho A, du Vivier AWP. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor α
antibody). Br J Dermatol 2006; 155:617-20. [PMID: 16911291 DOI: 10.1111/j.1365-2133.2006.07355.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We describe a patient with erythrodermic adult T-cell leukaemia/lymphoma resistant to multiple systemic therapies who, on the commencement of daclizumab, a humanized anti-interleukin-2 receptor antibody, developed a rapid and sustained complete response with resolution of previously debilitating erythroderma, suggesting significant activity of this agent in this disease process.
Collapse
Affiliation(s)
- G E N Osborne
- Departments of Dermatology and Haematology, King's College Hospital, Denmark Hill, London SE5 9RS, UK
| | | | | | | |
Collapse
|
26
|
Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24:6058-68. [PMID: 16155612 DOI: 10.1038/sj.onc.1208968] [Citation(s) in RCA: 642] [Impact Index Per Article: 33.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Epidemiologic aspects of human T-lymphotropic virus type I (HTLV-I) infection have been thoroughly studied over the course of approximately 25 years since its first description. The geographic distribution of the virus has been defined, with Japan, Africa, Caribbean islands and South America emerging as the areas of highest prevalence. The reasons for HTLV-I clustering, such as the high ubiquity in southwestern Japan but low prevalence in neighboring regions of Korea, China and eastern Russia are still unknown. The major modes of transmission are well understood, although better quantitative data on the incidence of transmission, and on promoting/inhibiting factors, are needed. Epidemiologic proof has been obtained for HTLV-I's causative role in major disease associations: adult T-cell leukemia (ATL), HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-associated uveitis and infective dermatitis. However, more and better studies are needed for other apparent disease outcomes such as rheumatologic, psychiatric and infectious diseases. Since curative treatment of ATL and HAM/TSP is lacking and a vaccine is unavailable, the social and financial cost for the individual, his/her family and the health system is immense. For this reason, public health interventions aimed at counseling and educating high-risk individuals and populations are of paramount importance.
Collapse
Affiliation(s)
- Fernando A Proietti
- Department of Social and Preventive Medicine, School of Medicine, Federal University of Minas Gerais, Avenida Alfredo Balena, 190, Belo Horizonte, Minas Gerais 30.130-100, Brazil.
| | | | | | | |
Collapse
|
27
|
Karpas A. Human retroviruses in leukaemia and AIDS: reflections on their discovery, biology and epidemiology. Biol Rev Camb Philos Soc 2005; 79:911-33. [PMID: 15682876 DOI: 10.1017/s1464793104006505] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The study of retroviruses has had a profound impact by unveiling an unusual form of viral replication: the multiplication of RNA viruses via a proviral DNA, for which Jan Svoboda provided the experimental model over forty years ago. In 1970 Temin, Mizutani and Baltimore discovered that this group of viruses contains a unique enzyme catalysing the synthesis of a DNA copy of the viral RNA: reverse transcriptase (RT). The discovery of RT has itself had an enormous impact on molecular biology in general, but also stimulated many premature claims of its detection in human disease. Claims by Gallo's laboratory that the cytoplasm of human leukaemia cells contained RT proved to be unfounded, as did his report in collaboration with Weiss that myeloid leukaemia contained HL23 virus, this organism proving not to be human but a laboratory contaminant of three monkey viruses. Conclusive demonstration of a retroviral involvement in human leukaemia was first provided in 1981 by Hinuma and his associates, showing that adult T-cell leukaemia (ATL), a rare form of leukaemia endemic to south-west Japan, is caused by a new retrovirus (ATLV). Other publications in December 1980 and through 1981 claimed the discovery of a new human T-cell leukaemia virus involved in mycosis fungoides (MF) and Sézary's syndrome (SS). This virus was termed HTLV by Gallo. The nucleotide sequence of ATLV is strongly conserved, that of my 1983 isolate from a black British ATL patient being practically identical with the Japanese virus isolates. After AIDS was recognised in 1981 by Gottlieb and coworkers as a new human disease, several papers were published by Gallo and his associates during 1983-4, invoking the oncovirus responsible for adult T-cell leukaemia as the cause of AIDS. In 1983 the French scientist Barré-Sinoussi and her colleagues succeeded in isolating a new agent in the disease, a lentivirus, which they named LAV. The French immunologist Klatzmann and his colleagues discovered that LAV killed CD4+ T-cells, furnishing an explanation for the pathogenesis of AIDS and providing a mechanism for how AIDS developed. For some time Gallo continued to suggest leukaemia virus involvement, claiming that his independent isolate of the AIDS virus, termed HTLV-III, was closely related to HTLV-I (the Japanese ATLV). Although this created considerable confusion among researchers for a period, the relationship was eventually disproved. Unlike ATLV, whose nucleic acid sequence is very stable, the AIDS virus (now termed HIV by international agreement) is extraordinarily unstable, the sequences of independent HIV isolates being quite unique: this made it possible to establish conclusively that both HTLV-III and another independent isolate CBL-1, from Weiss' laboratory, were actually LAV isolates from the French laboratory. It has been shown by Hayami and his associates that only African primates are infected with similar lentiviruses to HIV which explains why AIDS started in Africa. Further research has clarified the origin of HIV-1 to be a chimpanzee lentivirus and HIV-2 to be the sooty mangabey lentivirus, which began to spread in humans perhaps no more than fifty years ago. The infection has spread rapidly, primarily through sexual intercourse, but also by transmission through blood and its products as well as contaminated needles and syringes. Sexual intercourse has now spread the virus around the World; and there are probably some 70 million infected. 90% of those infected with HIV develop the deadly disease of AIDS within ten years of infection: the death toll from the disease has been enormous. By contrast, HTLV-1 has been infecting man in isolated areas probably for hundreds of years; but it has not spread widely. HTLV causes leukaemia in only less than 1% of those infected. The prime mode of transmission of HTLV-1 is between mother and neonate; infections can be reduced by stopping breast-feeding by infected mothers. The isolation of HIV enabled screening tests to be developed for contaminated blood. However, due to the peculiar biology of HIV infection, unfortunately all efforts to develop an effective vaccine have so far failed.
Collapse
Affiliation(s)
- Abraham Karpas
- Department of Haematology, University of Cambridge Clinical School, MRC Centre, Hills Road, Cambridge CB2 2QH, UK.
| |
Collapse
|
28
|
Eedy DJ, English JSC. Updates from the British Association of Dermatologists 84th annual meeting, 6-9 July 2004, Belfast, U.K. Br J Dermatol 2005; 152:13-28. [PMID: 15656796 DOI: 10.1111/j.1365-2133.2005.6413.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Herein is a synopsis of the main research and clinical findings presented at the British Association of Dermatologists meeting held during 6-9 July 2004, in Belfast, U.K. The conference highlighted the progress that has been made in understanding the increasing biological, epidemiological and therapeutic advances that have been made recently in the field of dermatology. The authors highlight the more important advances or summaries, but this is not meant as a substitute for reading the conference proceedings and related references quoted in this article.
Collapse
Affiliation(s)
- D J Eedy
- Craigavon Area Hospital Group Trust, 68 Lurgan Road, Portadown, BT63 5QQ, UK.
| | | |
Collapse
|
29
|
Abstract
Viruses are important pathogens in tropical areas; most of them, especially the tropical hemorrhagic fevers, produce mucocutaneous manifestations. More than any other kind of pathogen, viruses have the possibility for being widespread, since they have a greater probability of mutation than do bacteria, can cross species barriers easily, and infect both human beings and animals in habitats with a great biodiversity. Tropical habitats also have been subject to major ecologic changes in the last few decades, exposing humans to direct contact with these viruses and allowing hemorrhagic fevers due to new emergent viruses such as flaviviruses, filoviruses, arenaviruses, and hantaviruses to become major threats to public health. The collapse of eradication programs in many countries, as well as population increases and ecologic modifications, have led to the spread of dengue and yellow fever to large portions of the world owing to the dissemination of vectors, especially mosquitoes, with broad ecologic ranges. Viruses previously restricted to some geographic areas, such as Rift Valley fever, Crimean-Congo hemorrhagic fever, West Nile fever, and monkeypox are now affecting new countries and populations. Other viruses such as herpes B infection often affect travelers and animal handlers in most parts of the world. Dermatologic lesions occur in all these diseases and can facilitate a rapid diagnosis, leading to control of the virus and helping prevent possible outbreaks.
Collapse
Affiliation(s)
- Omar Lupi
- Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
| | | |
Collapse
|
30
|
Hoffbrand AV. Haematology at the Hammersmith Hospital and Royal Postgraduate Medical School 1934-1994. Br J Haematol 2003; 123:207-18. [PMID: 14531902 DOI: 10.1046/j.1365-2141.2003.04649.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- A V Hoffbrand
- Department of Haematology, Royal Free Hospital, London, UK
| |
Collapse
|
31
|
Franchini G, Fukumoto R, Fullen JR. T-Cell Control by Human T-Cell Leukemia/Lymphoma Virus Type 1. Int J Hematol 2003; 78:280-96. [PMID: 14686485 DOI: 10.1007/bf02983552] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) causes neoplastic transformation of human T-cells in a small number of infected individuals several years from infection. Collective evidence from in vitro studies indicates that several viral proteins act in concert to increase the responsiveness of T-cells to extracellular stimulation, modulate proapoptotic and antiapoptotic gene signals, enhance T-cell survival, and avoid immune recognition of the infected T-cells. The virus promotes T-cell proliferation by usurping several signaling pathways central to immune T-cell function, such as antigen stimulation and receptor-ligand interaction, suggesting that extracellular signals are important for HTLV-1 oncogenesis. Environmental factors such as chronic antigen stimulation may therefore be of importance, as also suggested by epidemiological data. Thus genetic and environmental factors together with the virus contribute to disease development. This review focuses on current knowledge of the mechanisms regulating HTLV-1 replication and the T-cell pathways that are usurped by viral proteins to induce and maintain clonal proliferation of infected T-cells. The relevance of these laboratory findings is related to clonal T-cell proliferation and adult T-cell leukemia/lymphoma development in vivo.
Collapse
Affiliation(s)
- Genoveffa Franchini
- Basic Research Laboratory, National Cancer Institute, Bethesda, Maryland 20892-5055, USA.
| | | | | |
Collapse
|
32
|
Franchini G, Nicot C, Johnson JM. Seizing of T Cells by Human T-Cell Leukemia⧸Lymphoma Virus Type 1. Adv Cancer Res 2003; 89:69-132. [PMID: 14587871 DOI: 10.1016/s0065-230x(03)01003-0] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) causes neoplastic transformation of human T-cells in a small number of infected individuals several years from infection. Several viral proteins act in concert to increase the responsiveness of T-cells to extracellular stimulation, modulate proapoptotic and antiapoptotic gene signals, enhance T-cell survival, and avoid immune recognition of the infected T-cells. The virus promotes T-cell proliferation by usurping several signaling pathways central to immune T-cell function. Viral proteins modulate the downstream effects of antigen stimulation and receptor-ligand interaction, suggesting that extracellular signals are important for HTLV-1 oncogenesis. Environmental factors such as chronic antigen stimulation are therefore important, as also suggested by epidemiological data. The ability of a given individual to respond to specific antigens is determined genetically. Thus, genetic and environmental factors, together with the virus, contribute to disease development. As in the case of other virus-associated cancers, HTLV-1-induced leukemia/lymphoma can be prevented by avoiding viral infection or by intervention during the asymptomatic phase with approaches able to interrupt the vicious cycle of virus-induced proliferation of a subset of T-cells. This review focuses on current knowledge of the mechanisms regulating HTLV-1 replication and the T-cell pathways that are usurped by viral proteins to induce and maintain clonal proliferation of infected T-cells in vitro. The relevance of these laboratory findings will be related to clonal T-cell proliferation and adult T-cell leukemia/lymphoma development in vivo.
Collapse
Affiliation(s)
- Genoveffa Franchini
- National Cancer Institute, Basic Research Laboratory, Bethesda, Maryland 20892, USA
| | | | | |
Collapse
|
33
|
Gallo RC. Human retroviruses after 20 years: a perspective from the past and prospects for their future control. Immunol Rev 2002; 185:236-65. [PMID: 12190935 DOI: 10.1034/j.1600-065x.2002.18520.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Among viruses the human retroviruses may be of special interest to immunologists, because they target cells of the immune system, particularly mature CD4+ T cells, impair their function and cause them to grow abnormally (human T-cell leukemia virus, HTLV) or to die (human immunodeficiency virus, HIV). Human retroviruses cause disease ranging from neurological disorders and leukemias (HTLV-1) to AIDS (acquired immunodeficiency virus) (HIV) and promote development of several types of malignancies (HIV). They share many common features, but their contrasts are greater, especially the far greater replication and variation of HIV associated with its greater genomic complexity. Both have evolved striking redundancy for mechanisms which promote their survival. Thus, HTLV has redundant mechanisms for promoting growth of provirus containing T cells needed for virus continuity, because it is chiefly through its cellular DNA provirus that HTLV replicates and not through production of virions. Conversely, HIV has redundancy in its mechanisms for promoting virion replication and escape from the host immune system. It is via these redundant mechanisms that they produce disease: leukemias from mechanisms promoting T-cell proliferation (HTLV-1) and AIDS from mechanisms promoting virus replication and T-cell death (HIV). The practical challenges for the future are clear. For HTLV-1, education and control of breastfeeding. For HIV, the formidable tasks now ahead in part demand new kinds of talent, talents that will foster greater insights into the development of therapy for the developing countries, new forms of less toxic therapies for all infected persons, a continued and expanded commitment to education, and a persistent 'never say die' commitment to the development of a truly preventive vaccine with all the scientific and nonscientific challenges that these objectives face.
Collapse
Affiliation(s)
- Robert C Gallo
- Institute of Human Virology, Department of Microbiology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
| |
Collapse
|
34
|
Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia 2002; 16:1069-85. [PMID: 12040438 DOI: 10.1038/sj.leu.2402458] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2001] [Accepted: 12/31/2001] [Indexed: 01/11/2023]
Abstract
Adult T cell leukemia/lymphoma (ATLL) is one of the peripheral T cell malignant neoplasms strongly associated with human T cell leukemia virus type-I (HTLV-I). Although the viral transactivating protein Tax has been proposed to play a critical role in leukemogeneis as shown by its transforming activity in various experimental systems, additional cellular events are required for the development of ATLL. One of the genetic events in ATLL is inactivation of tumor suppressor genes. Among many candidates for tumor suppressor genes, the main genetic events have been reported to center around the cyclin-dependent kinase inhibitors ((CDKIs) p15INK4A, p16INK4B, p18INK4C, p19INK4D, p21WAF1, p27KIP1, and p57KIP2), p53 and Rb genes; all of them play a major regulatory role during G1 to S transition in the cell cycle. Acute/lymphomatous ATLL has frequent alterations of p15 (20%) and p16 (28-67%), while chronic/smoldering ATLL has fewer abnormalities of p15 (0-13%) and p16 (5-26%). Most of these changes are deletion of the genes; fewer samples have mutations. ATLL patients with deleted p15 and/or p16 genes have significantly shorter survival than those individuals with both genes preserved. Although genetic alterations of p18, p19, p21, p27 have rarely been reported, inactivation of these genes may contribute to the development of ATLL because low expression levels of these genes seem to mark ATLL. The p53 gene is mutated in 10-50% of acute/lymphomatous ATLL. Functional impairment of the p53 protein, even if the gene has wild-type sequences, has been suggested in HTLV-I infected cells. Each of these genetic events are mainly found in acute/lymphomatous ATLL, suggesting that alterations of these genes may be associated with transformation to an aggressive phenotype. The Rb tumor suppressor gene is infrequently structurally altered, but one half of ATLL cases have lost expression of this key protein. Notably, alterations of one of the CDKIs, p53 and Rb genes appear to obviate the need for inactivation of other genes in the same pathway. A novel tumor suppressor gene on chromosome 6q may also have a critical role in the pathogenesis of ATLL. Taken together, tumor suppressor genes are frequently altered in acute/lymphomatous ATLL and their alteration is probably the driving force fueling the transition from chronic/smoldering to acute/lymphomatous ATLL.
Collapse
Affiliation(s)
- Y Hatta
- First Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan
| | | |
Collapse
|
35
|
Nakase K, Hasegawa M, Tsuji K, Ikeda T, Tamaki S, Tanigawa M, Miyanishi E, Shiku H. HTLV-1 unrelated adult T-cell leukemia/lymphoma with unique phenotype and karyotype. Am J Hematol 2000; 64:64-6. [PMID: 10815790 DOI: 10.1002/(sici)1096-8652(200005)64:1<64::aid-ajh11>3.0.co;2-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
We describe a unique case of adult T-cell leukemia/lymphoma (ATL). The patient had typical clinicohematological features as ATL, but showed a lack of antibody to human T-cell leukemia virus type-1 (HTLV-1) and was negative for HTLV-1 proviral DNA in the peripheral mononuclear cells by means of polymerase chain reaction. The phenotype of tumor cells revealed CD7+, CD5+, CD2+, CD3+, WT31-, TcR delta 1-, CD4-, CD8-, CD25-, and the karyotype showed a 5q-, t(12;18). HTLV-1 unrelated ATL is very rare, and the karyotype as in our case has not been reported previously.
Collapse
Affiliation(s)
- K Nakase
- Department of Internal Medicine, Saiseikai Matsusaka Hospital, Mie, Japan
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Pombo De Oliveira MS, Loureiro P, Bittencourt A, Chiattone C, Borducchi D, De Carvalho SM, Barbosa HS, Rios M, Sill A, Cleghorn F, Blattner W. Geographic diversity of adult t-cell leukemia/lymphoma in Brazil. The Brazilian ATLL Study Group. Int J Cancer 1999; 83:291-8. [PMID: 10495418 DOI: 10.1002/(sici)1097-0215(19991029)83:3<291::aid-ijc1>3.0.co;2-p] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We describe 195 cases of adult T-cell leukemia/lymphoma (ATLL) reported to the national registry of T-cell malignancies in Brazil between 1994 and 1998. We compared the effect of demographic differences and clinical features of 150 consecutive ATLL cases in different regions of this diverse country. At diagnosis, the predominant clinical sub-type was the acute type (60%), followed by lymphoma (22%), chronic (10%) and smoldering (8%) types. Although we expected that different sub-types would be present in different regions, on the basis of immunogenetic factors determined by ethnicity, we did not demonstrate these differences. There were no significant differences among ATLL subtypes by age or gender. No ethnic group predominated in the total population of patients, but significant differences were noted when examining ethnic distribution by region. Reflecting the general population distribution, white patients were seen more often in São Paulo and black patients in Bahia, than in other regions. In most regions, cases were equally distributed between blacks and mulattos, except in Pernambuco, where blacks were less frequent. The main clinical features were lymphadenopathy, skin lesions, hypercalcemia and hepatomegaly. Fourteen patients (9%) suffered from HTLV-I-associated myelopathy (HAM/TSP), either at diagnosis or during follow-up of ATLL. All cases but one had antibodies to HTLV-I, with concordant results with ELISA, WB and PCR analyses. For the antibody-negative case, pol and tax gene sequences were present in tumor cells when subjected to PCR analyses. The prognosis was generally poor, suggesting that the disease in Brazil behaves in similar fashion regardless of ethnic or geographical differences.
Collapse
Affiliation(s)
- M S Pombo De Oliveira
- Cell Markers Laboratory of Cancer Hospital, Instituto Nacional de Cancer, Rio de Janeiro, Brazil.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Horie R, Yatomi Y, Wakabayashi T, Ohno Y, Eriguchi M, Higashihara M, Nakahara K, Watanabe T. Primary gastric T-cell lymphomas: report of two cases and a review of the literature. Jpn J Clin Oncol 1999; 29:171-8. [PMID: 10225702 DOI: 10.1093/jjco/29.3.171] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
To understand more fully the clinicopathological features of primary gastric T-cell lymphomas (PGTL), we report two cases of PGTL and review the literature. The present cases were not associated with human T-cell leukemia virus type 1 (HTLV-1) and were at clinical stage IIE. In both cases, T-cell origin of the lymphoma cells was diagnosed immunohistochemically. The clinical courses of these two cases were different: one followed a very aggressive clinical course and the patient died 6 months after the diagnosis, whereas the other patient survived more than 2 years without adjuvant chemotherapy. Clinicopathological features of 23 patients with PGTL are summarized with regard to their differences from primary small intestinal T-cell lymphomas (PSITL) and by association with HTLV-1. The median age at onset of PGTL was 58 years. The gender ratio was male-dominant (M:F = 2.3:1). About two-thirds (10 of 17) of PGTL cases had evidence of HTLV-1 infection. The most common presenting symptom for PGTL was upper abdominal discomfort and/or pain (76%), whereas that in PSITL was weight loss (61%) and diarrhea (42%). Typical lesions for PGTL were large ulcerations at the corpus to antrum. Neoplastic cells had no typical morphological characteristics for PGTL including HTLV-1-associated cases. CD3+4+8- was the most frequently observed surface phenotype of PGTL cells. Laboratory findings at diagnosis were not informative. Most patients were treated by gastrectomy with or without chemotherapy. PGTL, excluding that with HTLV-1, showed better prognosis than PSITL, although PGTL with HTLV-1 had a poorer prognosis.
Collapse
Affiliation(s)
- R Horie
- Department of Pathology, Institute of Medical Science, University of Tokyo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Pawson R, Richardson DS, Pagliuca A, Kelsey SM, Hoque S, Breuer J, Newland AC, Mufti GJ. Adult T-cell leukemia/lymphoma in London: clinical experience of 21 cases. Leuk Lymphoma 1998; 31:177-85. [PMID: 9720727 DOI: 10.3109/10428199809057597] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is uncommon in the United Kingdom and has so far been restricted to people of Afro-Caribbean extraction. Between 1981 and 1995, 21 cases presented to 2 inner London teaching hospitals where 17% of the population are of Afro-Caribbean origin. Clinical presentations were similar to those of the disease in HTLV-I-endemic areas. Major responses (CR + PR) were obtained in 10/16 assessable patients (63%) treated with combination chemotherapy. However, median survival was only 5.5 months. Disease progression and opportunistic infection were the major causes of treatment failure and death. Three patients (14%) relapsed in the central nervous system (CNS). Our cases confirm the profound immunosuppression in ATLL. The poor prognosis of acute and lymphoma types of ATLL highlight the need for new approaches to treatment such as zidovudine and alpha-interferon, incorporating prophylaxis against CNS disease and opportunistic infections.
Collapse
Affiliation(s)
- R Pawson
- Department of Hematological Medicine, King's College Hospital School of Medicine and Dentistry, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Suzuki Y, Gojobori T. The origin and evolution of human T-cell lymphotropic virus types I and II. Virus Genes 1998; 16:69-84. [PMID: 9562892 DOI: 10.1023/a:1007953826869] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Studies on human T-cell lymphotropic virus types I (HTLV-I) and II (HTLV-II) are briefly reviewed from the viewpoint of molecular evolution, with special reference to the evolutionary rate and evolutionary relationships among these viruses. In particular, it appears that, in contrast to the low level of variability of HTLV-I among different isolates, individual isolates form quasispecies structures. Elucidating the mechanisms connecting these two phenomena will be one of the future problems in the study of the molecular evolution of HTLV-I and HTLV-II.
Collapse
Affiliation(s)
- Y Suzuki
- Center for Information Biology, National Institute of Genetics, Mishima, Japan
| | | |
Collapse
|
40
|
Tarsis SL, Yu MT, Parks ES, Persaud D, Muñoz JL, Parks WP. Human T-lymphocyte transformation with human T-cell lymphotropic virus type 2. J Virol 1998; 72:841-6. [PMID: 9420297 PMCID: PMC109446 DOI: 10.1128/jvi.72.1.841-846.1998] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Human T-cell lymphotrophic virus type 2 (HTLV-2), a common infection of intravenous drug users and subpopulations of Native Americans, is uncommon in the general population. In contrast with the closely related HTLV-1, which is associated with both leukemia and neurologic disorders, HTLV-2 lacks a strong etiologic association with disease. HTLV-2 does shares many properties with HTLV-1, including in vitro lymphocyte transformation capability. To better assess the ability of HTLV-2 to transform lymphocytes, a limiting dilution assay was used to generate clonal, transformed lymphocyte lines. As with HTLV-1, the transformation efficiency of HTLV-2 producer cells was proportionately related to the number of lethally irradiated input cells and was comparable to HTLV-1-mediated transformation efficiency. HTLV-2-infected cells were reproducibly isolated and had markedly increased growth potential compared to uninfected cells; HTLV-2 transformants required the continued presence of exogenous interleukin 2 for growth for several months and were maintained for over 2 years in culture. All HTLV-2-transformed populations were CD2 and/or CD3 positive and B1 negative and were either CD4+ or CD8+ populations or a mixture of CD4+ and CD8+ lymphocytes. Clonality of the HTLV-2 transformants was confirmed by Southern blot analysis of T-cell receptor beta chain rearrangement. Southern blot analysis revealed a range of integrated full-length genomes from one to multiple. In situ hybridization analysis of HTLV-2 integration revealed no obvious chromosomal integration pattern.
Collapse
Affiliation(s)
- S L Tarsis
- Department of Pediatrics, New York University Medical Center, New York 10016, USA
| | | | | | | | | | | |
Collapse
|
41
|
Mori N, Prager D. Transactivation of the interleukin-1 alpha promoter by human T-cell leukemia virus. Leuk Lymphoma 1997; 26:421-33. [PMID: 9389351 DOI: 10.3109/10428199709050880] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The expression of interleukin-1 alpha (IL-1 alpha) appears to be tightly regulated, as the levels of constitutive expression in normal cells is extremely low. In contrast to normal hematopoietic cells, human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines constitutively produce high levels of IL-1 alpha mRNA and secret this cytokine into the culture medium. IL-1-alpha mRNA is also expressed in fresh leukemic cells of adult T-cell leukemia/lymphoma (ATLL) patients. HTLV-I-induced IL-1 alpha might explain some symptoms observed in ATLL. In this regard, molecular dissection of the IL-1 alpha gene transcriptional regulation is of primary importance. In this review, the transcriptional regulation of IL-1 alpha gene expression and the possible role of the NF-kappaB pathway are discussed in the light of our current understanding of IL-1 alpha gene regulation by HTLV-I and HTLV-II Tax proteins, which are viral transcriptional transactivators.
Collapse
Affiliation(s)
- N Mori
- Department of Medicine, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, USA
| | | |
Collapse
|
42
|
Deardren C, Corbin D, Prussia P, Williams E, Hanshard B, Matutes E, Catovsky D. Clinical and laboratory features of adult T-cell leukaemia lymphoma in Barbados. Leuk Lymphoma 1996; 23:561-5. [PMID: 9031087 DOI: 10.3109/10428199609054865] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We describe the clinical and pathological features of 23 Afro-Caribbean patients with adult T-cell leukaemia/lymphoma admitted to the Queen Elizabeth Hospital, Barbados over a 5 year period. There were 9 males and 14 females, with a median age of 38 years (range 14-84). Twelve had acute leukaemia, 10 lymphoma (including 4 with solitary extra nodal lesions) and 1 smouldering subtype. Two patients had a past history of tropical spastic paraparesis/HTLV I associated myelopathy (TSP/HAM). The prognosis was poor, with only 3 complete responses to chemotherapy (CHOP) lasting from 9 to 36 months. We conclude that ATLL in Barbados is similar to the disease in the other Caribbean islands and Japan, except that in Barbados the age of onset is over a decade younger than in Japan.
Collapse
Affiliation(s)
- C Deardren
- Department of Medicine, Queen Elizabeth Hospital, St Michael, Barbados
| | | | | | | | | | | | | |
Collapse
|
43
|
Sandy GJ, Taylor J, Steiger M, Wearne M, Weber JN. HTLV-I associated uveitis: a report of two cases. Eye (Lond) 1996; 10 ( Pt 4):521-2. [PMID: 8944111 DOI: 10.1038/eye.1996.114] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
|
44
|
Feuer G, Fraser JK, Zack JA, Lee F, Feuer R, Chen IS. Human T-cell leukemia virus infection of human hematopoietic progenitor cells: maintenance of virus infection during differentiation in vitro and in vivo. J Virol 1996; 70:4038-44. [PMID: 8648741 PMCID: PMC190282 DOI: 10.1128/jvi.70.6.4038-4044.1996] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Human T-cell leukemia virus type I (HTLV-1) is the etiologic agent of adult T-cell leukemia and lymphoma and HTLV-1-associated myelopathy-tropical spastic paraparesis. We examined whether HTLV could productively infect human hematopoietic progenitor cells. CD34+ cells were enriched from human fetal liver cells and cocultivated with cell lines transformed with HTLV-1 and -2. HTLV-1 infection was established in between 10 and >95% of the enriched CD34+ cell population, as demonstrated by quantitative PCR analysis. HTLV-1 p19 Gag expression was also detected in infected hematopoietic progenitor cells. HTLV-1-infected hematopoietic progenitor cells were cultured in semisolid medium permissive for the development of erythbroid (BFU-E), myeloid (CFU-GM), and primitive progenitor (CFU-GEMM, HPP-CFC, or CFU-A) colonies. HTLV-1 sequences were detected in colonies of all hematopoietic lineages; furthermore, the ratio of HTLV genomes to the number of human cells in each infected colony was 1:1, consistent with each colony arising from a single infected hematopoietic progenitor cell. Severe combined immunodeficient mice engrafted with human fetal thymus and liver tissues (SCID-hu) develop a conjoint organ which supports human thymocyte differentiation and maturation. Inoculation of SCID-hu mice with HTLV-1-infected T cells or enriched populations of CD34+ cells established viral infection of thymocytes 4 to 6 weeks postreconstitution. Thymocytes from two mice with the greatest HTLV-1 proviral burdens showed increased expression of the CD25 marker and the interleukin 2 receptor alpha chain and perturbation of CD4+ and CD8+ thymocyte subset distribution profiles. Hematopoietic progenitor cells and thymuses may be targets for HTLV infection in humans, and these events may play a role in the pathogenesis associated with infection.
Collapse
Affiliation(s)
- G Feuer
- Department of Medicine, University of California at Los Angeles School of Medicine, 90095-1678, USA
| | | | | | | | | | | |
Collapse
|
45
|
Feigenbaum L, Fujita K, Collins FS, Jay G. Repression of the NF1 gene by Tax may expain the development of neurofibromas in human T-lymphotropic virus type 1 transgenic mice. J Virol 1996; 70:3280-5. [PMID: 8627811 PMCID: PMC190194 DOI: 10.1128/jvi.70.5.3280-3285.1996] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
In familial neurofibromatosis type 1 (NF1), individuals with a germ line-transmitted NF1 mutation develop multiple neurofibromas. To explain the observation that transgenic mice expressing the human T-lymphotropic virus type 1 (HTLV-1) tax gene under the control of the viral regulatory element also develop multiple neurofibromas, we demonstrate that the Tax trans-regulator can functionally repress NF1 gene expression through a cis-acting element located immediately upstream of its transcriptional start site, thereby allowing the development of benign neurofibromas without the need for direct mutations in NF1. We propose that such a mechanism would suffice to epigenetically alter NF1 gene expression. The fact that transgenic animals have localized rather than diffuse neurofibroma formation, however, suggests that additional genetic or epigenetic events may be required for neurofibroma formation.
Collapse
Affiliation(s)
- L Feigenbaum
- Department of Virology, Jerome H. Holland Laboratory, Rockville, Maryland 20855, USA
| | | | | | | |
Collapse
|
46
|
Taylor GP. The epidemiology of HTLV-I in Europe. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY : OFFICIAL PUBLICATION OF THE INTERNATIONAL RETROVIROLOGY ASSOCIATION 1996; 13 Suppl 1:S8-14. [PMID: 8797697 DOI: 10.1097/00042560-199600001-00003] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Although human T-lymphotropic virus type I (HTLV-I) infection in Europe is thought to be unusual except amongst people who have immigrated from countries where HTLV-I is endemic, the screening of blood donors has revealed a low seroprevalence across Europe, not only in donors originating from endemic areas but also in the indigenous population. Data from blood donors should not be extrapolated to other groups because blood donors are selected to be at low risk of parenterally transmissible infections. Unfortunately only small studies have been conducted in other population groups, including women attending antenatal clinics, despite the importance of breast-feeding in vertical transmission. Data from metropolitan areas of the United Kingdom and France suggest that the seroprevalence of HTLV-I in pregnant women is up to 100 times higher than in blood donors. HTLV-I infection is also more common in patients attending sexually transmitted disease clinics, whilst HTLV-II is endemic in many cities amongst intravenous drug users. There are few incidence data for diseases associated with HTLV-I, even though cases of adult T-cell leukemia/lymphoma and HTLV-I-associated myelopathy have been described in many European countries. Data on the seroprevalence of HTLV-I in central and eastern Europe are scanty but the few published studies suggest a higher rate than has been documented in western Europe.
Collapse
Affiliation(s)
- G P Taylor
- St. Mary's Hospital Medical School, London, England, UK
| |
Collapse
|
47
|
Takatsuki K, Matsuoka M, Yamaguchi K. Adult T-cell leukemia in Japan. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY : OFFICIAL PUBLICATION OF THE INTERNATIONAL RETROVIROLOGY ASSOCIATION 1996; 13 Suppl 1:S15-9. [PMID: 8797698 DOI: 10.1097/00042560-199600001-00004] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Adult T-cell leukemia (ATL) was first reported in Japan, where it has a high incidence in the southwestern region. The retrovirus, human T-lymphotropic virus type I (HTLV-I), is found to be the causative agent of ATL. In ATL-endemic areas, the rate of HTLV-I carriers is high. A definite diagnosis of ATL is based on the presence of HTLV-I proviral DNA in the tumor cell DNA. ATL cells originate from the CD4 subset of peripheral T cells. ATL shows diverse clinical features but can be divided into four subtypes: the acute, chronic, smoldering, and lymphoma types. Chemotherapy is not effective; the acute and lymphoma types have a poor prognosis. Familial occurrence of ATL is common. HTLV-I infection is caused by transmission of live infected lymphocytes from mother to child, or from man to woman, or by blood transfusion.
Collapse
Affiliation(s)
- K Takatsuki
- Kumamoto University School of Medicine, Japan
| | | | | |
Collapse
|
48
|
Bunn PA, Foss FM. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL). JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT 1996; 24:12-23. [PMID: 8806090 DOI: 10.1002/jcb.240630503] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Efforts at the National Cancer Institute to generate continuous in vitro cultures from patients with mycosis fungoides and the Sezary syndrome, neoplasms with a mature T-helper phenotype, led to the establishment of two cell lines, HUT78 and HUT102. Further characterization of these cell lines led to the identification of the first human retrovirus, HTLV-1, in the HUT102 cells, and the clinical description of the syndrome of HTLV-1 associated acute T-cell leukemia/lymphoma; the serum antibody test to screen for this virus was developed from the serum of the patient from whom the cell line was derived. The HUT78 cell line was pivotal in the identification and characterization of the HIV retrovirus in that a subclone, H9, proved to be permissive for replication of HIV in vitro. Propagation of HIV in vitro in H9 cells allowed for the development of immunological reagents to screen blood supplies for the presence of the virus. Further biologic and molecular studies of these lines have led not only to a better understanding of the underlying diseases but also to the development of rational therapeutic approaches.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal/therapeutic use
- Antimetabolites, Antineoplastic/therapeutic use
- Cytokines/biosynthesis
- Cytokines/genetics
- Cytokines/therapeutic use
- Gene Expression Regulation, Neoplastic
- HIV/isolation & purification
- HIV Infections/history
- HIV Infections/pathology
- HIV Infections/virology
- HTLV-I Infections/epidemiology
- HTLV-I Infections/history
- HTLV-I Infections/pathology
- HTLV-I Infections/virology
- History, 20th Century
- Human T-lymphotropic virus 1/isolation & purification
- Humans
- Immunologic Factors/therapeutic use
- Leukemia-Lymphoma, Adult T-Cell/genetics
- Leukemia-Lymphoma, Adult T-Cell/pathology
- Leukemia-Lymphoma, Adult T-Cell/virology
- Lymphoma, AIDS-Related/history
- Lymphoma, AIDS-Related/pathology
- Lymphoma, AIDS-Related/virology
- Lymphoma, T-Cell, Cutaneous/genetics
- Lymphoma, T-Cell, Cutaneous/pathology
- Lymphoma, T-Cell, Cutaneous/therapy
- Male
- Middle Aged
- Mycosis Fungoides/genetics
- Mycosis Fungoides/pathology
- Mycosis Fungoides/virology
- National Institutes of Health (U.S.)/history
- Neoplasm Proteins/biosynthesis
- Neoplasm Proteins/genetics
- Prevalence
- Proto-Oncogenes
- Receptors, Cytokine/biosynthesis
- Receptors, Cytokine/genetics
- Sezary Syndrome/genetics
- Sezary Syndrome/pathology
- Sezary Syndrome/virology
- Skin Neoplasms/genetics
- Skin Neoplasms/pathology
- Skin Neoplasms/therapy
- Skin Neoplasms/virology
- T-Lymphocytes, Helper-Inducer/pathology
- Tumor Cells, Cultured/virology
- United States
Collapse
Affiliation(s)
- P A Bunn
- University of Colorado Cancer Center, Denver 80262, USA
| | | |
Collapse
|
49
|
Cereseto A, Mulloy JC, Franchini G. Insights on the pathogenicity of human T-lymphotropic/leukemia virus types I and II. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY : OFFICIAL PUBLICATION OF THE INTERNATIONAL RETROVIROLOGY ASSOCIATION 1996; 13 Suppl 1:S69-75. [PMID: 8797707 DOI: 10.1097/00042560-199600001-00013] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Human T-lymphotropic/leukemia virus types I and II (HTLV-I and HTLV-II) are phylogenetically and immunologically related viruses that differ in their pathogenicity in vivo. HTLV-I is the etiologic agent of adult T-cell leukemia/lymphoma, as well as a chronic progressive myelopathy, HTLV-I-associated myelopathy/tropical spastic paraparesis. In contrast, HTLV-II has not been conclusively associated with specific diseases. Both HTLV-I and HTLV-II transform CD4+ T-cells in vitro, but their in vivo target cells appear to differ. HTLV-I is found mainly in CD4+ cells, whereas HTLV-II has been demonstrated mainly in CD8+ cells. Clearly the definition of the viral genetic determinants responsible for the different tropism and pathogenicity in vivo may provide the basis of our understanding of the HTLV-I oncogenicity. In this short review we emphasize two aspects of viral infection of T cells: (1) the influence of viral infection on the major proteins involved in the G0-G1 phase of the cell cycle and (2) the effect of viral infection on the S phase of the cell cycle, i.e., the interleukin-2 receptor pathway.
Collapse
Affiliation(s)
- A Cereseto
- Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA
| | | | | |
Collapse
|
50
|
Tóth FD, Aboagye-Mathiesen G, Szabó J, Liu X, Mosborg-Petersen P, Kiss J, Hager H, Zdravkovic M, Andirkó I, Aranyosi J. Bidirectional enhancing activities between human T cell leukemia-lymphoma virus type I and human cytomegalovirus in human term syncytiotrophoblast cells cultured in vitro. AIDS Res Hum Retroviruses 1995; 11:1495-1507. [PMID: 8679294 DOI: 10.1089/aid.1995.11.1495] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
The syncytiotrophoblast layer of the human placenta has an important role in limiting transplacental viral spread from mother to fetus. Human cytomegalovirus (HCMV) is capable of establishing a latent infection in syncytiotrophoblast cells, with restriction of gene expression to immediate-early and early proteins. We analyzed the extent of replication of human T cell leukemia-lymphoma virus type I (HTLV-I) in human term syncytiotrophoblasts infected with HTLV-I alone or coinfected with HTLV-I and HCMV. Although syncytiotrophoblasts could be infected with cell-free HTLV-I, no viral protein expression was found in the singly infected cells. On the contrary, coinfection of the cells with HTLV-I and HCMV resulted in simultaneous replication of both viruses. Bidirectional enhancing activities between HTLV-I and HCMV were mediated primarily by the Tax and immediate-early proteins, respectively. The stimulatory effect of HTLV-I Tax on HCMV replication appeared to be mediated partly by tumor necrosis factor beta and transforming growth factor beta-1. We observed formation of pseudotypes with HTLV-I nucleocapsids within HCMV envelopes, whereas HCMV was not pseudotyped by HTLV-I envelopes in dually infected syncytiotrophoblast cells. Our data suggest that in vivo dual infection of syncytiotrophoblast cells with HTLV-I and HCMV may facilitate the transplacental transmission of both viruses.
Collapse
Affiliation(s)
- F D Tóth
- Department of Virus and Cancer, Danish Cancer Society, Aarhus, Denmark
| | | | | | | | | | | | | | | | | | | |
Collapse
|